As the leading provider of generic contrast agents, Fresenius Kabi’s commitment is to provide you with choice and value – by continuing to grow their radiology portfolio. We look forward to seeing you at RSNA 2025 | Booth #3247 | South Hall 

Six years ago, two radiologists with dissimilar backgrounds and divergent clinical interests put their heads together and launched a new practice. One physician was an academic subspecialized in musculoskeletal reads. The other, a private practitioner, concentrated on oncologic imaging. That’s how Transparent Imaging was born, powered by Konica Minolta. 

Identifying the signs of severe aortic stenosis is typically a fairly straightforward process for cardiologists. In some cases, however, the patient’s symptoms present in a way that is outside of the norm. 

Prosthesis-patient mismatch (PPM) is the phenomenon that occurs when the effective orifice area of a prosthetic heart valve isn’t adequately sized to meet a patient’s blood flow requirements. More is known today about PPM than ever before—but there is still so much to learn. 

In a private dining room in Miami, something unusual is happening. Leaders from competing imaging centers are openly discussing their best practices—even sharing vendor recommendations and operational strategies that have doubled their volumes while cutting costs in half.

Pulmonary embolism (PE) remains one of the leading causes of cardiovascular death in the United States. TriStar Health, part of HCA Healthcare, has made PE a priority by bringing together a multidisciplinary team and adopting AI-enabled workflows to support timely diagnosis and treatment. This approach is designed to drive consistent, high-quality care – whether patients are seen at a large hospital or a community ER.

Market-savvy radiologists recognize the shortage of talent in their profession as a challenging yet exciting opportunity. More patients and referrers are ready to be served—and greater compensation is ripe to be earned.  

Atrial fibrillation (AFib), the most common heart rhythm disorder, continues to rise globally - it is predicted to affect more than 12 million people in the US by 2030 and almost 18 million people in Europe by 2060. With a growing aging population and an increased prevalence of heart disease, the demand for effective treatments for AFib is higher than ever before.